Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Prediction of PLK1 PBD activity based on deep learning

Prediction of Small Molecule Kinase Inhibitors for Chemotherapy Using Deep Learning

Improving drug response prediction via integrating gene relationships with deep learning

PECAN Predicts Patterns of Cancer Cell Cytostatic Activity of Natural Products Using Deep Learning

Calibrated geometric deep learning improves kinase–drug binding predictions

AI-based prediction of protein–ligand binding affinity and discovery of potential natural product inhibitors against ERK2

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

A deep learning-based method for drug-target interaction prediction based on long short-term memory neural network

Learning the Cellular Activity Representation Based on Gene Regulatory Networks for Prediction of Tumor Response to Drugs

Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity

Large-scale comparison of machine learning methods for profiling prediction of kinase inhibitors

SYNERGY OF ADVANCED MACHINE LEARNING AND DEEP NEURAL NETWORKS WITH CONSENSUS MOLECULAR DOCKING FOR ENHANCED POTENCY PREDICTION OF ALK INHIBITORS

Predicting the target landscape of kinase inhibitors using 3D convolutional neural networks

A deep learning method for drug-target affinity prediction based on sequence interaction information mining

Deep-belief network for predicting potential miRNA-disease associations

SPLDExtraTrees: robust machine learning approach for predicting kinase inhibitor resistance

Imputation of Assay Bioactivity Data Using Deep Learning

A method combining LDA and neural networks for antitumor drug efficacy prediction

Predicting drug activity against cancer through genomic profiles and SMILES